|MDACC Study No:||2013-0873 (clinicaltrials.gov NCT No: NCT01993641)|
|Title:||A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients with Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone|
|Principal Investigator:||Guillermo Garcia-Manero|
|Treatment Agent:||Azacitidine; Decitabine; Pracinostat|
|Study Description:||The goal of this clinical research study is to learn if adding pracinostat to |
the drug that you have already received (azacitidine or decitabine) can help to
control MDS. The safety of this drug combination will also be studied.